This latest twist in the Lykos Therapeutics saga threatens An important overhaul of the corporation’s strategy and course, with Musk ally and billionaire investor Antonio Gracias showing to wish to take the business back again toward its nonprofit drug advancement roots and a more Doblinite philosophy.Patent programs are key for 18 months, and wh